A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants
Latest Information Update: 30 May 2025
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Migraine
- Focus Registrational; Therapeutic Use
- Acronyms C-BEOND
- Sponsors Ipsen
Most Recent Events
- 29 Mar 2024 Planned End Date changed from 31 Dec 2025 to 21 Dec 2026.
- 29 Mar 2024 Planned primary completion date changed from 31 Jul 2025 to 22 Jun 2026.
- 22 Dec 2023 Planned End Date changed from 31 Jul 2025 to 31 Dec 2025.